Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 1005-1016

  Ludwig, Agnieszka Honorata ^a   Murawska, Magdalena ^a   Panek, Grzegorz ^a   Timorek, Agnieszka ^b   Kupryjanczyk, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Brodnowski Hospital Warsaw   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANDROGEN RECEPTOR; CYTIDINE; FOLLITROPIN RECEPTOR; GUANIDINE; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; PROTEIN P53; TAXANE DERIVATIVE; TRINUCLEOTIDE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, ANDROGEN; RECEPTORS, FSH; RECEPTORS, PROGESTERONE; RISK; YOUNG ADULT;

EID: 70349259140     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0135     Document Type: Article

References (45)

1. Belsham DD, Yee WC, Greenberg CR & Wrogemann K 1992 Analysis of the CAG repeat region of the androgen receptor gene in a kindred with X-linked spinal and bulbar muscular atrophy. Journal of Neurological Sciences 112 133-138.
2. Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM et al. 2004 Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiology, Biomarkers and Prevention 13 2141-2147. (Pubitemid 40054309)
3. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA et al. 2004 Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics 13 1677-1692. (Pubitemid 39173438)
4. Chamberlain NL, Driver ED & Miesfeld RL 1994 The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 22 3181-3186.
5. Christian MC & Trimble EL 1994 Salvage chemotherapy for epithelial ovarian carcinoma. Gynecologic Oncology 55 S143-S150.
6. Cramer DW & Welch WR 1983 Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute 71 717-721. (Pubitemid 14232385)
7. Didkowska J, Wojciechowska U, Tarkowski W & Zatonski W 2007 Cancer in Poland in 2005, p 143. Warsaw, Poland: Institute of Oncology.
8. Ding D, Xu L, Menon M, Reddy GP & Barrack ER 2005 Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62 133-139. (Pubitemid 40096779)
9. Fathalla MF 1971 Incessant ovulation - a factor in ovarian neoplasia? Lancet 2 163.
10. Ferro P, Catalano MG, Dell'Eva R, Fortunati N & Pfeffer U 2002 The androgen receptor CAG repeat: a modifier of carcinogenesis? Molecular and Cellular Endocrinology 193 109-120.
11. Gao T, Marcelli M & McPhaul MJ 1996 Transcriptional activation and transient expression of the human androgen receptor. Journal of Steroid Biochemistry and Molecular Biology 59 9-20. (Pubitemid 27014137)
12. Heubner M, Riemann K, Otterbach F, Kimmig R, Kasimir-Bauer S, Siffert W & Wimberger P 2009 The haplotype of two FSHR polymorphisms in ovarian cancer - a potential role of ethnology in risk modification. Gynecologic Oncology 112 486-489.
13. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J & Chang C 2000 Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Research 60 5111-5116. (Pubitemid 30739768)
14. Huhtaniemi I & Alevizaki M 2006 Gonadotrophin resistance. Best Practice and Research. Clinical Endocrinology and Metabolism 20 561-576.
15. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR & Coetzee GA 2000 Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Human Molecular Genetics 9 267-274. (Pubitemid 30052750)
16. Kupryjańczyk J 2006 Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses. Gynecologic Oncology 100 5-7. (Pubitemid 41815041)
17. Kupryjańczyk J, Szymańska T, Madry R, Timorek A, Stelmachów J, Karpińska G, Rembiszewska A, Ziół kowska I, Kraszewska E, Debniak J et al. 2003 Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. British Journal of Cancer 88 848-854. (Pubitemid 36520871)
18. Kupryjańczyk J, Madry R, Plisiecka-Hałasa J, Bar J, Kraszewska E, Ziółkowska I, Timorek A, Stelmachów J, Emerich J, Jedryka M et al. 2004 TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. British Journal of Cancer 91 1916-1923. (Pubitemid 40065521)
19. Kupryjańczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M & Pocsg PO 2008 TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a nonrandomized retrospective study. BMC Cancer 8 27.
20. Li AJ, Baldwin RL & Karlan BY 2003 Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clinical Cancer Research 9 3667-3673. (Pubitemid 37169233)
21. Li AJ, Elmore RG, Pavelka JC & Karlan BY 2007 Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecologic Oncology 107 420-423.
22. Li AJ, Scoles DR, Armstrong KU & Karlan BY 2008 Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecologic Oncology 109 220-225.
23. Lundin KB, Giwercman A, Dizeyi N & Giwercman YL 2007 Functional in vitro characterisation of the androgen receptor GGN polymorphism. Molecular and Cellular Endocrinology 264 184-187. (Pubitemid 46097313)
24. Miller AB, Hoogstraten B, Staquet M & Winkler A 1981 Reporting results of cancer treatment. Cancer 47 207-214.
25. Modugno F 2004 Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. American Journal of Epidemiology 159 319-335. (Pubitemid 38200765)
26. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA & Narod SA 2000 Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. Journal of Urology 164 567-572. (Pubitemid 30481985)
27. Pearce CL, Wu AH, Gayther SA, Bale AE, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R et al. 2008 Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. British Journal of Cancer 98 282-288.
28. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E & Simoni M 2000 Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. Journal of Clinical Endocrinology and Metabolism 85 3365-3369. (Pubitemid 30944552)
29. Rao BR & Slotman BJ 1991 Endocrine factors in common epithelial ovarian cancer. Endocrine Reviews 12 14-26.
30. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 90 1774-1786.
31. Risch HA, Bale AE, Beck PA & Zheng W 2006 PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention 15 1738-1741. (Pubitemid 44497112)
32. Romano A, Lindsey PJ, Fischer DC, Delvoux B, Paulussen AD, Janssen RG & Kieback DG 2006 Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecologic Oncology 101 287-295.
33. Santarosa M, Bidoli E, Gallo A, Steffan A, Boiocchi M & Viel A 2002 Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. Oncology Reports 9 639-644.
34. Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR et al. 2007 Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention 16 473-480. (Pubitemid 46562346)
35. Simoni M, Gromoll J, Hoppner W, Kamischke A, Krafft T, Stahle D & Nieschlag E 1999 Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. Journal of Clinical Endocrinology and Metabolism 84 751-755. (Pubitemid 29075716)
36. La Spada AR, Wilson EM, Lubahn DB, Harding AE & Fischbeck KH 1991 Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352 77-79.
37. Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL & Chenevix-Trench G 2000 Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. International Journal of Cancer 87 637-643. (Pubitemid 30620404)
38. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ & Fujimoto S 2002 Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Molecular Human Reproduction 8 893-899. (Pubitemid 35174921)
39. Tavassoli AF & Devilee P 2003 Pathology of Genetics of Tumors of Breast and Female Genital Organs. WHO Classification of Tumors. Lyon, France: IARC Press.
40. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC & Cramer DW 2005a Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Research 65 5974-5981. (Pubitemid 40911205)
41. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM & Cramer DW 2005b Genetic variation in the progesterone receptor gene and ovarian cancer risk. American Journal of Epidemiology 161 442-451. (Pubitemid 40315615)
42. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA & Hunter DJ 2002 A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. PNAS 99 12263-12268.
43. Wooster R & Weber BL 2003 Breast and ovarian cancer. New England Journal of Medicine 348 2339-2347.
44. Yang CQ, Chan KY, Ngan HY, Khoo US, Chiu PM, Chan QK, Xue WC & Cheung AN 2006 Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 27 1502-1506. (Pubitemid 43985424)
45. Ziółkowska-Seta I, Madry R, Kraszewska E, Szymańska T, Timorek A, Rembiszewska A & Kupryjańczyk J 2009 TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecologic Oncology 112 179-184.